Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression

Liver cancer is one of the most lethal malignancies and is commonly diagnosed as hepatocellular carcinoma (HCC), a tumor type that affects about 90% of patients. Non-alcoholic steatohepatitis (NASH) and obesity are both risk factors for this disease. HCC initiation and progression are deeply linked...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2022-09, Vol.10 (10), p.2344
Main Authors: da Cruz, Nathalia Soares, Pasquarelli-do-Nascimento, Gabriel, E Oliveira, Augusto Cézar Polveiro, Magalhães, Kelly Grace
Format: Article
Language:English
Subjects:
Apoptosis
Chemokines
Cytokines
Disease
HCC
Hepatitis C
Hepatocellular carcinoma
IL-1β
Inflammasomes
Inflammation
Interleukin 18
Ligands
Liver cancer
Liver diseases
Metabolism
Metastasis
Microenvironments
NASH
Obesity
Physiological aspects
Proteins
Review
Risk factors
Therapeutic targets
Tumors
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver cancer is one of the most lethal malignancies and is commonly diagnosed as hepatocellular carcinoma (HCC), a tumor type that affects about 90% of patients. Non-alcoholic steatohepatitis (NASH) and obesity are both risk factors for this disease. HCC initiation and progression are deeply linked with changes in the hepatic microenvironment, with cytokines playing key roles. The understanding of the pathogenic pathways that connect these disorders to liver cancer remains poor. However, the inflammasome-mediated cytokines associated with both diseases are central actors in liver cancer progression. The release of the pro-inflammatory cytokines IL-1β and IL-18 during inflammasome activation leads to several detrimental effects on the liver microenvironment. Considering the critical crosstalk between obesity, NASH, and HCC, this review will present the connections of IL-1β and IL-18 from obesity-associated NASH with HCC and will discuss approaches to using these cytokines as therapeutic targets against HCC.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines10102344